Huang Xiao-Min, Zhong Xing, Du Yi-Jun, Guo Yan-Yun, Pan Tian-Rong
Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.
World J Diabetes. 2023 Aug 15;14(8):1280-1288. doi: 10.4239/wjd.v14.i8.1280.
Currently, the lack of comparative studies between weekly and daily formulations of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for glucose excursion is worth investigation.
To investigate the effects of weekly and daily formulations of GLP-1RA on glucose excursion and inflammation in overweight and obese patients with type 2 diabetes.
Seventy patients with type 2 diabetes mellitus who were treated at our hospital between January 2019 and January 2022 were enrolled in this retrospective analysis. All patients were treated with metformin. We evaluated changes in blood glucose levels and a series of important indicators in patients before and after treatment with either a weekly or daily preparation of GLP-1RA (group A; = 33 and group B; = 37).
The degree of decrease in the levels of fasting blood glucose, mean blood glucose, mean amplitude of glycemic excursions, total cholesterol, triglycerides, tumor necrosis factor-α, interleukin-6, and high-sensitivity C-reactive protein after treatment in group A was higher than that in group B ( < 0.05), whereas the 2-h postprandial blood glucose levels decreased more so in group B than in group A ( < 0.001). However, there were no statistically significant differences in the levels of glycated hemoglobin, standard deviation of blood glucose, coefficient of variation, absolute mean of daily differences, percentage of time with 3.9 mmol/L < glucose < 10 mmol/L, and high- and low-density lipoproteins between the two groups ( > 0.05). The incidence of adverse reactions was significantly lower in group A than in group B ( < 0.05).
The effect of the weekly preparation of GLP-1RA in controlling blood glucose levels in the patients, suppressing inflammation, and reducing adverse reactions was significantly higher than that of the daily preparations, which is worthy of clinical promotion.
目前，胰高血糖素样肽-1受体激动剂（GLP-1RAs）每周一次和每日一次剂型在血糖波动方面缺乏对比研究，值得探讨。
研究GLP-1RA每周一次和每日一次剂型对超重和肥胖2型糖尿病患者血糖波动及炎症的影响。
纳入2019年1月至2022年1月在我院接受治疗的70例2型糖尿病患者进行回顾性分析。所有患者均接受二甲双胍治疗。我们评估了患者在接受每周一次或每日一次GLP-1RA制剂治疗（A组；n = 33，B组；n = 37）前后血糖水平及一系列重要指标的变化。
A组治疗后空腹血糖、平均血糖、血糖波动平均幅度、总胆固醇、甘油三酯、肿瘤坏死因子-α、白细胞介素-6和高敏C反应蛋白水平的下降程度高于B组（P < 0.05），而餐后2小时血糖水平B组下降幅度大于A组（P < 0.001）。然而，两组之间糖化血红蛋白水平、血糖标准差、变异系数、每日差异绝对值均值、血糖在3.9 mmol/L <血糖< 10 mmol/L的时间百分比以及高密度和低密度脂蛋白水平无统计学显著差异（P > 0.05）。A组不良反应发生率显著低于B组（P < 0.05）。
GLP-1RA每周一次制剂在控制患者血糖水平、抑制炎症及减少不良反应方面的效果显著高于每日一次制剂，值得临床推广。
